title: [Effect of acupoint-injection of oxymatrine on experimental hepatic carcinoma and study on the mechanism].
abstract: OBJECTIVE
  To investigate the effect of acupoint injection of oxymatrine (OM) on experimental hepatocellular carcinoma and the mechanism.
  
  
  METHODS
  The rats of hepatocellular carcinoma induced by 2-acetoaminoflurence (2-AAF) were randomly divided into a normal control group (group N), a model group (group M), a control group of oxymatrine intraperitoneal injection (OM ip group) and a treatment group of small dose oxymatrine injection into Zusanli (OM ZSL group). At the end of 12h week, the serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma-glutamyl transferase (gamma-GT) were determined. Reverse transcription polymerase chain reaction (RT-PCR) was used to detect the expressions of cyclin D1 and cyclin-dependent kinase 4 (CDK4) mRNA in hepatocellular carcinoma tissues.
  
  
  RESULTS
  The number of cancer nodes on the surface of liver in th Om ip group and the Om ZSL group was lower than in the group M, with the serum ALT, AST, and gamma-GT levels significantly decreased (P<0. 01), and significantly inhibited expressions of cyclin D1, CDK4 mRNA (P<0. 01).
  
  
  CONCLUSIONS
  OM ip and small dose oxymatrine injection into ZSL can treat or delay hepatocarcinogenisis of hepatocellular carcinoma induced by 2-AAF. Partial mechanism of this anti-carcinoma is protecting hepatocytes possibly through improving hepatic functions, and inhibiting excessive proliferation of liver cancer cells via inhibiting the expressions of cyclin Dl, CDK4 mRNA.
authors: Medical College of Nantong University, Jiangsu 226001, China. ailingzhou0513@163.com
authors: Ai-ling
authors: AL
authors: Zhou
authors: Yu-juan
authors: YJ
authors: Zhu
authors: Ya-e
authors: YE
authors: Hu
authors: Jia-hui
authors: JH
authors: Mao
authors: Dao-rong
authors: DR
authors: Jiang
mesh_terms: D015669:Acupuncture Points; D000410:Alanine Transaminase / Q000097:blood; D000470:Alkaloids / Q000008:administration & dosage*; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D019938:Cyclin D1 / Q000235:genetics; D051358:Cyclin-Dependent Kinase 4 / Q000235:genetics; D007267:Injections; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy*; D008297:Male; D011807:Quinolizines / Q000008:administration & dosage*; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D005723:gamma-Glutamyltransferase / Q000097:blood; D000093842:Matrines
chemical_list: D000410:Alanine Transaminase; D000470:Alkaloids; D001219:Aspartate Aminotransferases; D019938:Cyclin D1; D051358:Cyclin-Dependent Kinase 4; D011807:Quinolizines; D012333:RNA, Messenger; D005723:gamma-Glutamyltransferase; C037573:oxymatrine; D000093842:Matrines